Diamond Hill Capital’s Top Stock Picks

Ric Dillon is head honcho at the $8+ billion Diamond Hill Capital Management. The firm is publicly traded on the NASDAQ under the ticker DHIL and is part of the Russell 2000 Index. Diamond Hill takes long-term approach to capital management and believes heavily in the concept of reversion to intrinsic value. In this article we will take a closer look at Diamond Hill Capital’s top stock picks:

CompanyName Ticker Value Activity
OCCIDENTAL PETROLEUM CORP OXY 279521 -2%
ANADARKO PETROLEUM CORP APC 258996 -1%
UNITED TECHNOLOGIES CORP UTX 246877 -2%
ABBOTT LABORATORIES ABT 226778 -2%
PFIZER INC PFE 213616 -1%
MEDTRONIC INC MDT 210037 -2%
PROCTER & GAMBLE CO PG 205784 1%
MICROSOFT CORP MSFT 192065 -7%
PEPSICO INC PEP 191440 -4%
P N C FINANCIAL SERVICES GRP PNC 181597 -3%

Occidental Petroleum Corporation (NYSE:OXY)

Occidental Petroleum (NYSE: OXY) has been lagging in recent history. We too have not been thrilled by capital spending overruns and awful reserve replacements in the past year and a half. To stem the bloodshed, the company has made a couple moves. It hired a new EVP of Operations, Willie Chiang. He was rumored to be in the running for the top job at Phillips 66 but that went to Greg Garland. Chiang’s expertise has been in refining, so we’re not sure how that will translate into better performance at OXY but we’ll just have to see. With shares below $80, we thought the company would be buying back shares like mad. However, this has not materialized. In Q1 calls, CEO Chazen did indicate that buybacks would take place, and we think they will. If share repurchases get OXY to a 7% cash yield this year, there is no way the stock should trade below $80, especially with improvements in California. We’re in as are Ralph Whitworth, Leighton Welch, and Robert Bishop.

Anadarko Petroleum (NYSE: APC) has been operating smoothly thus far with decent FCF generation. The stock is trading relatively in line with its large cap peers. And though we think there are additional unlocked sources of value in West Africa (offshore), the Gulf of Mexico, and other resource play programs, until the Tronox trial is over, we would not recommend establishing a position. In this $25 billion environmental lawsuit, Tronox and the US government are up against APC and Kerr-McGee that will assign blame for Tronox’s “toxic past.” Chemical maker, Tronox, had filed for Chapter 11 in 2009. In terms of what investors expect, according to a Credit Suisse survey, 65% of respondents believe the valuation embeds more than $1.5 billion for Tronox, including 31% between $1.5 and $2.5 billion and 34% above $2.5 billion. APC management does not seem to want to settle, so we expect this to get dirty.

United Technologies (NYSE: UTX) is an industrial conglomerate with brands like Otis (world’s largest elevator company), Carrier (commercial/residential heating and air-conditioning systems and commercial transport refrigeration equipment), Pratt & Whitney (supplies military and civil aircraft engines and service operations), and Sikorsky (helicopters). UTX is a major player in aerospace and defense as well as global infrastructure, and we think the company can continue to post solid results accompanied by share repurchases given its substantial FCF conversion. However, we don’t see many upcoming catalysts and would prefer a global operator with more ex-US sales (UTX derives 60 percent of sales from the US).

Abbott Laboratories (NASDAQ: ABT), like other big pharma companies, faces a looming patent cliff. It currents dominates the autoimmune market, an estimated $25 billion market that includes treatment for rheumatoid arthritis, Crohn’s disease, Addison’s disease, multiple sclerosis, and type I diabetes. ABT’s Humira is the world’s best-selling drug in the autoimmune market, with an estimated market share of well over 30% (mostly to treat rheumatoid arthritis). 2011 Humira revenues were over $8 billion, and we think this could accelerate to $10.5 billion by 2013. However, ABT’s HIV antiviral, Kaletra, has been losing market share in part because of exclusion from the list of preferred treatment options in some US Department of Health and Human Services’ (DHHS) guidelines. Overall ABT has a decent pipeline but we prefer pharma companies with catalysts and a strong pipeline like Pfizer (read more on Why Hedge Funds Love Pfizer).

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!